+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Peptide Therapeutics Market (2022-2027) by Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 210 Pages
  • August 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5669575

On February 21, 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less

The Global Peptide Therapeutics Market is estimated to be USD 29.84 Bn in 2022 and is expected to reach USD 48.19 Bn by 2027, growing at a CAGR of 10.06%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Peptide Therapeutics Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks.

Market Segmentations

The Global Peptide Therapeutics Market is segmented based on Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography.
  • By Synthesis Technology, the market is classified into Hybrid Phase, Liquid Phase, and Solid Phase.
  • By Drug Class, the market is classified into Calcitonin's, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin.
  • By Route of Administration, the market is classified into Parenteral and Oral.
  • By API Type, the market is classified into CMO and In-house.
  • By Application, the market is classified into Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications.
  • By End User, the market is classified into Hospitals, Pharmaceutical Industries, and Research Laboratories.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ag, Merck & Co., Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Zealand Pharma AS, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Peptide Therapeutics Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global Peptide Therapeutics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Peptide Therapeutics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains a competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Peptide Therapeutics Market

What is the estimated value of the Global Peptide Therapeutics Market?

The Global Peptide Therapeutics Market was estimated to be valued at $29.84 Billion in 2022.

What is the growth rate of the Global Peptide Therapeutics Market?

The growth rate of the Global Peptide Therapeutics Market is 10.0%, with an estimated value of $48.19 Billion by 2027.

What is the forecasted size of the Global Peptide Therapeutics Market?

The Global Peptide Therapeutics Market is estimated to be worth $48.19 Billion by 2027.

Who are the key companies in the Global Peptide Therapeutics Market?

Key companies in the Global Peptide Therapeutics Market include AmbioPharm Inc., Amgen Inc., AstraZeneca PLC, Bachem Holding Ag, Bristol, Myers Squibb Company, Corden Pharma GmbH, Eli Lilly and Company and La Roche Ag.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 IGR Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing Prevalence of Cancer, Cardiovascular Disorders, and Metabolic Disorders
4.1.2 Adoption of New Platforms That Develop Next-Generation Protein or Peptide Therapeutics
4.2 Restraints
4.2.1 Poor Chemical and Physical Stability and a Short Circulating Plasma Half-Life of Naturally Occurring Peptides
4.3 Opportunities
4.3.1 Technology Advancement and R&D Investment in New Peptides
4.3.2 Presence of a Strong Product Pipeline Portfolio
4.4 Challenges
4.4.1 Presence of Stringent Safety Regulations
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
5.5 PESTLE Analysis
6 Global Peptide Therapeutics Market, By Synthesis Technology
6.1 Introduction
6.2 Hybrid Phase
6.3 Liquid Phase
6.4 Solid Phase
7 Global Peptide Therapeutics Market, By Drug Class
7.1 Introduction
7.2 Calcitonin's
7.3 Glucagon & Analogs
7.4 Insulins
7.5 Luteinizing Hormone-Releasing Hormone
7.6 Somatostatins
7.7 Vasopressin
8 Global Peptide Therapeutics Market, By Route of Administration
8.1 Introduction
8.2 Parenteral
8.3 Oral
9 Global Peptide Therapeutics Market, By API Type
9.1 Introduction
9.2 CMO
9.3 In-house
10 Global Peptide Therapeutics Market, By Application
10.1 Introduction
10.2 Gastrointestinal Disorders
10.3 Neurological Disorders
10.4 Metabolic Disorders
10.5 Cancer
10.6 Other Applications
11 Global Peptide Therapeutics Market, By End User
11.1 Introduction
11.2 Hospitals
11.3 Pharmaceutical Industries
11.4 Research Laboratories
12 Americas' Peptide Therapeutics Market
12.1 Introduction
12.2 Argentina
12.3 Brazil
12.4 Canada
12.5 Chile
12.6 Colombia
12.7 Mexico
12.8 Peru
12.9 United States
12.10 Rest of Americas
13 Europe's Peptide Therapeutics Market
13.1 Introduction
13.2 Austria
13.3 Belgium
13.4 Denmark
13.5 Finland
13.6 France
13.7 Germany
13.8 Italy
13.9 Netherlands
13.10 Norway
13.11 Poland
13.12 Russia
13.13 Spain
13.14 Sweden
13.15 Switzerland
13.16 United Kingdom
13.17 Rest of Europe
14 Middle East and Africa's Peptide Therapeutics Market
14.1 Introduction
14.2 Egypt
14.3 Israel
14.4 Qatar
14.5 Saudi Arabia
14.6 South Africa
14.7 United Arab Emirates
14.8 Rest of MEA
15 APAC's Peptide Therapeutics Market
15.1 Introduction
15.2 Australia
15.3 Bangladesh
15.4 China
15.5 India
15.6 Indonesia
15.7 Japan
15.8 Malaysia
15.9 Philippines
15.10 Singapore
15.11 South Korea
15.12 Sri Lanka
15.13 Thailand
15.14 Taiwan
15.15 Rest of Asia-Pacific
16 Competitive Landscape
16.1 IGR Competitive Quadrant
16.2 Market Share Analysis
16.3 Strategic Initiatives
16.3.1 M&A and Investments
16.3.2 Partnerships and Collaborations
16.3.3 Product Developments and Improvements
17 Company Profiles
17.1 AmbioPharm Inc.
17.2 Amgen Inc.
17.3 AstraZeneca PLC
17.4 Bachem Holding Ag
17.5 Bristol-Myers Squibb Company
17.6 Corden Pharma GmbH
17.7 Eli Lilly and Company
17.8 F. Hoffmann-La Roche Ag
17.9 GSK PLC
17.10 Hemmo Pharmaceuticals Pvt. Ltd.
17.11 Ipsen SA
17.12 Merck & Co., Inc.
17.13 Novartis International Ag
17.14 Novo Nordisk AS
17.15 Pfizer Inc.
17.16 PolyPeptide Group
17.17 Sanofi SA
17.18 Takeda Pharmaceutical Co.Ltd.
17.19 Teva Pharmaceutical Industries Ltd.
17.20 Zealand Pharma AS
18 Appendix
18.1 Questionnaire

Companies Mentioned

  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding Ag
  • Bristol-Myers Squibb Company
  • Corden Pharma GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ag
  • GSK PLC
  • Hemmo Pharmaceuticals Pvt. Ltd.
  • Ipsen SA
  • Merck & Co., Inc.
  • Novartis International Ag
  • Novo Nordisk AS
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi SA
  • Takeda Pharmaceutical Co.Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma AS